SEC FIlings Archives - Page 18 of 19

06 Jan

SEC FIlings

Notice of Effectiveness

November 17, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Registration adding securities to prior Form S-1 registration

November 17, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Certification

November 17, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Registration of securities

November 17, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

06 Jan

SEC FIlings

Initial statement of beneficial ownership of securities

December 14, 2022
Posted by Jitendra

05 Jan

SEC FIlings

Correspondence

November 17, 2022
Posted by Jitendra

05 Jan

SEC FIlings

Correspondence

November 17, 2022
Posted by Jitendra

SEC FIlings

Notice of Effectiveness

Registration adding securities to prior Form S-1 registration

Certification

Registration of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Initial statement of beneficial ownership of securities

Correspondence

Correspondence

test according

Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information

Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without

Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists